How a ketogenic diet could reduce autoimmune disease severity through host-microbiome interactions

Sanofi and BioN­Tech scrapped de­vel­op­ment of an mR­NA ther­a­py that can be in­ject­ed in­to a tu­mor af­ter see­ing re­sults from an in­ter­im analy­sis. Sanofi on

Syn­cona, the ma­jor­i­ty share­hold­er of Free­line Ther­a­peu­tics, has made a bid to ac­quire the biotech less than a month af­ter it re­vealed da­ta from two